Showing 1,401 - 1,420 results of 116,331 for search '(( a non decrease ) OR ( 5 ((point decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.04s Refine Results
  1. 1401
  2. 1402

    Receptor specific silencing decreases NGF induced apoptosis. by Alessandra Micera (294762)

    Published 2013
    “…A 37.5%-decrease (*) and a 50%-decrease (**) of apoptotic signal were detected respectively in p75<sup>NTR</sup>-siRNA and p75<sup>NTR</sup>/trkA<sup>NGFR</sup>-siRNA (p<.05).…”
  3. 1403

    Postnatal CDPPB treatment decreased [<sup>11</sup>C]PBR accumulation in saline-exposed offspring, but not in offspring prenatally exposed to LPS. by Dany Arsenault (229311)

    Published 2015
    “…<p>Postnatal CDPPB treatment decreased the accumulation of [<sup>11</sup>C]PBR in the olfactory bulb, cerebellum, hippocampus, striatum, hypothalamus and the whole brain of the offspring prenatally exposed to saline solution (A). …”
  4. 1404
  5. 1405
  6. 1406

    Relationship between Differential Hepatic microRNA Expression and Decreased Hepatic Cytochrome P450 3A Activity in Cirrhosis by Raj Vuppalanchi (458660)

    Published 2013
    “…The relative expression (2<sup>-ΔΔCt</sup> mean ± SEM) of hepatic CYP3A4 mRNA was significantly higher in cirrhotic livers (21.76 ± 2.65 vs. 5.91 ± 1.29, P=2.04E-07) but their levels did not significantly correlate with hepatic CYP3A activity (r=-0.43, P=0.08).…”
  7. 1407
  8. 1408

    Decreased HIF levels associated with hyperoxic cell state. by Julie M. Koeman (108185)

    Published 2008
    “…<p>(A) Normalized densitometry of HIF-1α protein levels (•),HIF-1β protein levels (▴), and HIF-1 DNA-binding activity (⧫) as presented in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1000176#pgen-1000176-g005" target="_blank">Figure 5B</a> of the Jiang et al. article. …”
  9. 1409
  10. 1410
  11. 1411
  12. 1412
  13. 1413

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  14. 1414
  15. 1415
  16. 1416
  17. 1417
  18. 1418
  19. 1419

    Knockdown of VGLUT1 results in a concomitant decrease in synaptic expression of synapsin and synaptophysin. by Corbett T. Berry (296520)

    Published 2013
    “…(<b>E</b>) Synaptophysin was not decreased in KD neurons co-expressing VGLUT1 (<i>V1</i>, VGLUT1 expressing neurons; p = 0.940; n = 244 and 96 puncta from 13 and 9 axons for SCR and V1, respectively, from a representative experiment. …”
  20. 1420

    Deterioration of the anammox process at decreasing temperatures and long SRTs by Maaike Hoekstra (3915545)

    Published 2017
    “…The long SRT leads to an increase of non-active and non-anammox cells in the reactor, thereby decreasing the biomass-specific activity.…”